Tue, Apr 22, 2:45 PM, Zacks
Sarepta Soars on Eteplirsen Submission Plans - Analyst Blog
Sarepta shares soared over 39% after the company announced it would submit a NDA for eteplirsen by year end.
Tue, Apr 22, 9:49 AM, Zacks
Keep an Eye on these 3 Biotech Stocks - Earnings ESP
This sell-off was more due to a change in sentiment rather than a shift in industry fundamentals.